Press Release | October 09, 2019 | Source: Oncologie – The initiated study will further evaluate the antitumor activity, safety and tolerability of bavituximab plus KEYTRUDA® in a gastric cancer population – Oncologie’s first global study for bavituximab plans enrollment in the US, UK, Taiwan and......
Press Release | August 12, 2019 | Source: Oncologie WALTHAM, Mass., Aug. 12, 2019 — Oncologie, Inc., a clinical-stage biopharmaceutical company developing innovative oncology treatments targeting the tumor microenvironment, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the......
News Article | June 07, 2018 | Source: Oncologie, Inc. BOSTON and SHANGHAI, June 7, 2018 /PRNewswire/ — Oncologie, an innovative biopharmaceutical company, announced today that it is launching operations in both Boston and Shanghai with $16.5M seed financing led by Pivotal bioVenture Partners China. Oncologie is......
Press Release | February 13, 2018 | Source: Mologen BERLIN–(BUSINESS WIRE)–The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today the signing of a license deal for the Chinese territory and a global co-development agreement between MOLOGEN and ONCOLOGIE Inc. for......
Press Release | February 12, 2018 | Source: Avid Bioservices, Inc. TUSTIN, Calif. and BOSTON, Feb. 12, 2018 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Oncologie, Inc. today announced that the companies have entered into an Asset Assignment and Purchase Agreement for......
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Click here to review our Privacy Policy.